Rights and permissions
About this article
Cite this article
Gemcitabine + vinorelbine less toxic but no QOL advantage. Pharmacoecon. Outcomes News 430, 10 (2003). https://doi.org/10.1007/BF03276800
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03276800